Unless otherwise indicated, this information has been self-reported and has not been
verified by the Board of Medicine.
Publications
(up to ten in the last five years)
Last Updated 7/4/2022
U.S. Patent Office and multiple foreign countries
Date: 01 2009
Methods of inducing immune responses to HIV-1 by administering UV/psoralen-treated desialated inactivated HIV-1 virions deficient in CD55 and CD59, U.S. Patent 7892562 B2
U.S. Patent Office and multiple foreign countries
Date: 01 2009
Method of inducing immune response in a host by administering immunogenic compositions comprising UV- irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particles devoid of CD55 and CD59 in the viral membrane U.S. Patent 7
U.S. Patent Office and Patent Office multiple foreign countries
Date: 04 2010
Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site U.S.Patent 07718180
U.S. Patent Office and Patent Office multiple foreign countries
Date: 05 2010
Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site U.S. Patent 07786288
U.S. Patent Office and Patent Office multiple foreign countries
Date: 08 2010
Immunizing compositions comprising recombinant attenuated self-replicating viral RNA replicons encoding an epitope obtained from the HIV-1 matrix protein myristate binding site U.S. Patent 7790177
U.S. Patent Office and multiple foreign Patent Offices
Date: 09 2010
Methods of inducing TH-1 immune responses to HIV-1 by administering UV/psoralen-treated desialated inactivated HIV-1 virions deficient in CD55 and CD59 U.S. Patent 07892562
U.S. Patent Office and Patent Office multiple foreign countries
Date: 02 2011
Immunogenic composition and method of developing a vaccine based on fusion protein U.S. Patent 20110104196-A1
U.S. Patent Office and Patent Office multiple foreign countries
Date: 05 2011
Method of inducing immune response in a host by administering immunogenic compositions comprising UV- irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) particlesdevoid
Date: 01 2014
